Effective Treatments in Psychiatry

2011 ◽  
Author(s):  
Peter Tyrer ◽  
Kenneth R. Silk
Keyword(s):  
Effective Treatments

Application of Monoterpenoids and their Derivatives for Treatment of Neurodegenerative Disorders

2019 ◽  
Vol 25 (39) ◽  
pp. 5327-5346 ◽  
Author(s):  
Konstantin P. Volcho ◽  
Sergey S. Laev ◽  
Ghulam Md Ashraf ◽  
Gjumrakch Aliev ◽  
Nariman F. Salakhutdinov
Keyword(s):  
Alzheimer’S Disease ◽  
Clinical Trials ◽  
Huntington's Disease ◽  
Neurodegenerative Disorders ◽  
Heterogeneous Group ◽  
Neuroprotective Activity ◽  
Severe Loss ◽  
Neurotrophic Activity ◽  
Full Proof ◽  
Effective Treatments

Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.

scholarly journals Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Chenxia Hu ◽  
Lingfei Zhao ◽  
Lingjian Zhang ◽  
Qiongling Bao ◽  
Lanjuan Li
Keyword(s):  
Stem Cell ◽  
Liver Injury ◽  
Mesenchymal Stem Cell ◽  
Effective Treatments

scholarly journals Debridement and corpectomy via single posterior approach to treat pyogenic spondylitis after vertebral augmentation

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Shuai Zhang ◽  
Song Wang ◽  
Qing Wang ◽  
Jin Yang ◽  
Shuang Xu
Keyword(s):  
Severe Pain ◽  
Neurological Deficits ◽  
Spinal Stability ◽  
Vertebral Augmentation ◽  
Pathogenic Microorganisms ◽  
Surgical Time ◽  
Pyogenic Spondylitis ◽  
Single Posterior Approach ◽  
Posterior Debridement ◽  
Effective Treatments

Abstract Background Infection after vertebral augmentation (VA) often limits the daily activities of patients and even threatens their life. The operation may be one of the effective treatments if the patient suffers from intolerable severe pain, neurological deficits, and damage to spinal stability. This study aimed to investigate the clinical efficacy of the treatment of pyogenic spondylitis after vertebral augmentation (PSVA) with Single posterior debridement, vertebral body resection, and intervertebral bone graft fusion and internal fixation (sPVRIF). Methods The study was performed on 19 patients with PSVA who underwent VA at 4 hospitals in the region between January 2010 and July 2020. Nineteen patients were included. Among them, 16 patients underwent sPVRIF to treat the PSVA. Results A total of 2267 patients underwent VA at 4 hospitals in the region. Of the 19 patients with postoperative PSVA, suppurative spondylitis was misdiagnosed as an osteoporotic vertebral fracture(OVF) in 4 patients and they underwent VA. Besides osteoporosis, 18 patients had other comorbidities. The average interval between the first surgery and the diagnosis of PSVA was 96.4 days. Of the 19 patients, 16 received surgical treatment. The surgical time was 175.0±16.8 min, and the intraoperative blood loss was 465.6±166.0 mL. Pathogenic microorganisms were cultured in 12 patients. Conclusion PSVA is a severe complication that can even threaten the life of the patients. sPVRIF may be one of the effective treatments if the patient suffers from intolerable severe pain, neurological deficits, and damage to spinal stability.

Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells

2021 ◽  
Author(s):  
Yiran Zheng ◽  
Jessica Kng ◽  
Chuan Yang ◽  
James Hedrick ◽  
Yi Yan Yang
Keyword(s):  
Drug Resistance ◽  
Cancer Cells ◽  
Cationic Polymer ◽  
Effective Treatments

Chemotherapy is one of the most effective treatments for cancer. However, toxicity and the development of drug resistance have become the major hurdles to the commonly used chemotherapeutics such as...

Pharmacy Leadership Amid the Pandemic: Maintaining Patient Safety During Uncertain Times

2021 ◽  
pp. 001857872110375
Author(s):  
Irene Derrong Lin ◽  
John B. Hertig
Keyword(s):  
Patient Safety ◽  
Safety Data ◽  
Clinical Effectiveness ◽  
World Health ◽  
Leadership Strategies ◽  
Pharmaceutical Supply Chain ◽  
The World ◽  
Health Organization ◽  
Pharmacy Leaders ◽  
Effective Treatments

The relentless surges of global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections that caused the Covid-19 disease had pressured researchers and regulators to develop effective treatments quickly. While studying these therapies amid the pandemic, threats to patient care were reported, including (1) maintaining adequate safeguards as clinical effectiveness and safety data evolves, (2) risks from online counterfeit medications, and (3) disruption of the global pharmaceutical supply chain. This article discusses these patient safety threats and suggests strategies that promote patient safety, foster medication intelligence, and mitigate drug shortages. As the world continues to develop safe and effective treatments for Covid-19, patient safety is paramount. In response to the World Health Organization (WHO) Global Safety Challenge: Medication Without Harm, leaders must establish effective approaches to improve medication safety during the pandemic. Successfully integrating these leadership strategies with current practices allows pharmacy leaders to implement robust systems to reduce errors, prevent harm, and advocate for patient safety.

scholarly journals Epidemiology and Management of Children with Hypertensive Crisis: A Single-Center Experience

2019 ◽  
Vol 09 (01) ◽  
pp. 045-050
Author(s):  
Alicia May Lim ◽  
Siew Le Chong ◽  
Yong Hong Ng ◽  
Yoke Hwee Chan ◽  
Jan Hau Lee
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Hypertensive Crisis ◽  
Hypertensive Emergency ◽  
Renal Pathology ◽  
Pediatric Hospital ◽  
Single Center ◽  
Single Center Experience ◽  
Effective Treatments

AbstractMost children who present with hypertensive crisis have a secondary cause for hypertension. This study describes the epidemiology and management of children with hypertensive crisis. A retrospective cohort study was done in a tertiary pediatric hospital from 2009 to 2015. Thirty-seven patients were treated for hypertensive crisis. Twelve (32.4%) patients were treated for hypertensive emergency. The majority of our patients (33 [89.1%]) had a secondary cause of hypertension. The most common identifiable cause of hypertension was a renal pathology (18/37 [48.6%]). Oral nifedipine (23 [62.1%]) was the most frequently used antihypertensive, followed by intravenous labetalol (8 [21.6%]). There were no mortalities or morbidities. Hypertensive crisis in children is likely secondary in nature. Oral nifedipine and intravenous labetalol are both effective treatments.

Sign in / Sign up

Export Citation Format

Share Document